Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Grace F. Crotty"'
Publikováno v:
Frontiers in Aging Neuroscience, Vol 12 (2020)
Exercise may be the most commonly offered yet least consistently followed therapeutic advice for people with Parkinson’s disease (PD). Epidemiological studies of prospectively followed cohorts have shown a lower risk for later developing PD in heal
Externí odkaz:
https://doaj.org/article/918af729e3504fa18eb9de9a96ee6668
Publikováno v:
Neurology. 99:34-41
Despite the sound epidemiologic and basic science rationales underpinning numerous “disease modification” trials in manifest Parkinson disease (PD), none has convincingly demonstrated that a treatment slows progression. Rapidly expanding knowledg
Autor:
Jisoo Kim, Geoffrey S. Young, Andrew S. Willett, Ariana T. Pitaro, Grace F. Crotty, Merlyne Mesidor, Kristie A. Jones, Camden Bay, Min Zhang, Mel B. Feany, Xiaoyin Xu, Lei Qin, Vikram Khurana
Publikováno v:
The Cerebellum.
Differentiating multiple system atrophy (MSA) from related neurodegenerative movement disorders (NMD) is challenging. MRI is widely available and automated decision-tree analysis is simple, transparent, and resistant to overfitting. Using a retrospec
Publikováno v:
Movement Disorders. 35:1727-1730
Autor:
Manuel Montalban, Xiqun Chen, Jamal I. Alkabsh, Sarah Huntwork-Rodriguez, Michael A. Schwarzschild, Giuseppe Astarita, Junhua Wang, Eric A. Macklin, Rachit Bakshi, Alberto Ascherio, Romeo Maciuca, Sonnet S. Davis, Grace F. Crotty
Publikováno v:
Neurology. 95:e3428-e3437
ObjectiveTo identify markers of resistance to developing Parkinson disease (PD) among LRRK2 mutation carriers (LRRK2+), we carried out metabolomic profiling in individuals with PD and unaffected controls (UC), with and without the LRRK2 mutation.Meth
Autor:
Grace F. Crotty, Jessi L. Keavney, Roy N. Alcalay, Kenneth Marek, Gad A. Marshall, H. Diana Rosas, Michael A. Schwarzschild
Publikováno v:
Neurology. 99(7 Suppl 1)
Parkinson disease (PD) is a chronic progressive neurodegenerative disease with increasing worldwide prevalence. Despite many trials of neuroprotective therapies in manifest PD, no disease-modifying therapy has been established. Over the past several
Autor:
Daniela Berg, Grace F. Crotty, Jessi L. Keavney, Michael A. Schwarzschild, Tanya Simuni, Caroline Tanner
Publikováno v:
Neurology. 99(7 Suppl 1)
Tremendous progress in our understanding of the pathophysiology and clinical manifestations of the prodromal phase of Parkinson disease (PD) offers a unique opportunity to start therapeutic interventions as early as possible to slow or even stop the
Autor:
Tanya Simuni, Holly A. Shill, Matthew Brodsky, Marcie Rabin, Michael A. Schwarzschild, Kenneth Marek, Cheryl Waters, Cindy Casaceli, Steven A. Gunzler, Stephen G. Reich, Codrin Lungu, Sarah Elizabeth Zauber, Kellie Keith, Shyamal H. Mehta, Dariush Mozaffarian, Valerie Suski, Marie Saint-Hilaire, John L. Goudreau, Alice Rudolph, Ruth B. Schneider, Aaron Daley, Eric A. Macklin, Zoltan Mari, Grace F. Crotty, Andres Deik, Alberto J. Espay, Ashley Laroche, Sherri Mosovsky, Joohi Jimenez-Shahed, Mark S. LeDoux, Cynthia Poon, Ashley Gerald, John C. Morgan, Carolyn Peterson, Joseph H. Friedman, David Klements, Robert A. Hauser, Doozie Russell, David Simon, Kathrin LaFaver, Vanessa K. Hinson, Richard B. Dewey, Melissa Ainslie, Jason Aldred, Tiago A. Mestre, John Y. Fang, Liana S. Rosenthal, Grace Bwala, Raymond C. James, Binit B. Shah, Gearoid M. McMahon, Ariane Park, Rajeev Kumar, Lin Zhang, Ivan Bodis-Wollner, Mya C. Schiess, Katherine F. Callahan, David Oakes, Kelvin L. Chou, Melissa Kostrzebski, Roger Kurlan, Lisa Gauger, Albert Y. Hung, Melissa Bixby, Ira Shoulson, Michael Soileau, James T. Boyd, Peter A LeWitt, Burton L. Scott, Claire Henchcliffe, Patricia Kaminski, Alberto Ascherio, Cornelia Kamp, Lindsay Pothier, Anwar Ahmed, Jill Ciccarello, David J. Houghton, April Langhammer, Rebecca Fitzgerald, Maureen A. Leehey, Anthony E. Lang, Carmen Serrano, Martha McGraw, David Shprecher, Jennifer Durphy, Aleksandar Videnovic, Danish Bhatti, Christine Hunter, Amber Servi Ratel, J. Antonelle de Marcaida, Christopher G. Goetz, Emily Houston, Rajesh Pahwa, Chadwick W. Christine, Gary C. Curhan, Irene Litvan, Christopher A. Beck, Leslie J. Cloud, Patrick Bolger, Karen Thomas, Natividad Stover, Karen Blindauer, Sushrut S. Waikar, Susan R. Criswell
Publikováno v:
JAMA
IMPORTANCE: Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e4608ea519947a922d23da1991ccca9
https://europepmc.org/articles/PMC8441591/
https://europepmc.org/articles/PMC8441591/
Publikováno v:
Practical Neurology. 19:316-320
We present two historic cases of severe encephalopathy associated with antithyroid antibodies. The first was published by Lord Brain of Eynsham, and the second was from our department’s archives. Although both cases are from archival sources, they
Autor:
Eric A. Macklin, Michael A. Schwarzschild, Rachit Bakshi, Grace F. Crotty, Ning Xia, Robert Logan, Alberto Ascherio, Xiqun Chen, Ellen Zhang, Musab M. Zorlu
Publikováno v:
Annals of Neurology. 85:593-599
OBJECTIVE LRRK2 mutations, the most common genetic cause of Parkinson disease (PD), display incomplete penetrance, indicating the importance of other genetic and environmental influences on disease pathogenesis in LRRK2 mutation carriers. The present